article thumbnail

Cleerly Launches Cleerly ISCHEMIA Solution for Heart Disease Analysis

DAIC

milla1cf Tue, 01/09/2024 - 11:32 January 9, 2024 — Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, announced the launch of Cleerly ISCHEMIA , which recently received U.S. Cleerly ISCHEMIA is a transformative addition poised to reshape the landscape of cardiac care.”

Ischemia 119
article thumbnail

Cleerly ISCHEMIA Software Device Billable With AMA Category I CPT Code for Noninvasive Estimates of Fractional Flow Reserve

DAIC

milla1cf Fri, 02/23/2024 - 11:54 February 23, 2024 — Cleerly , the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Prior studies have demonstrated the independent and incremental benefit of Cleerly ISCHEMIA applied to CCTA beyond traditional assessment.

Ischemia 105
article thumbnail

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

DAIC

milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.

article thumbnail

The effect of individual exercise rehabilitation program on ischemic burden and cardiac function in patients with ischemic non-obstructive coronary heart disease: a randomized parallel controlled clinical trial

Frontiers in Cardiovascular Medicine

BackgroundCoronary heart disease (CHD) is a pervasive chronic condition that poses a significant threat to global health and mortality worldwide. TIB in the intervention group was significantly reduced at the 1,2, and 4-week marks post-intervention and exhibited a higher effective rate of total myocardial ischemia load reduction.

article thumbnail

Two promising approaches in the treatment of myocardial infarction: stem cells and gene therapy

Frontiers in Cardiovascular Medicine

CVDs include coronary heart disease, stroke, hypertension, and peripheral vascular diseases. In China, the death rate of CVDs ranks the first in all major diseases. At present, the main methods to treat ischemic heart disease are drug therapy, intervention and operation.

article thumbnail

Correlation between CT-derived fractional flow reserve and myocardial strain in ischemic heart disease patients with single coronary artery stenosis assessed based on CCTA

Frontiers in Cardiovascular Medicine

CTFFR can identify impaired myocardial strain and can be used as an indirect indicator of myocardial ischemia.

article thumbnail

Revascularization enhances quality of life for patients with chronic limb threatening ischemia

Science Daily - Heart Disease

Over 200 million people around the world experience peripheral artery disease (PAD) -- a condition caused by the narrowing of the blood vessels from the heart to the lower limbs that leads to pain when walking -- and for roughly 1-in-10 this advances to chronic limb-threatening ischemia (CLTI), an advanced form of PAD.